Bibliografías temáticas / Low molecular weight heparin / Libros

Libros sobre el tema "Low molecular weight heparin"

Siga este enlace para ver otros tipos de publicaciones sobre el tema: Low molecular weight heparin.
Autor: Grafiati
Publicado: 4 de junio de 2021
Última modificación: 10 de marzo de 2023

Crea una cita precisa en los estilos APA, MLA, Chicago, Harvard y otros

Elija tipo de fuente:

Consulte los 50 mejores mejores libros para su investigación sobre el tema "Low molecular weight heparin".

Junto a cada fuente en la lista de referencias hay un botón "Agregar a la bibliografía". Pulsa este botón, y generaremos automáticamente la referencia bibliográfica para la obra elegida en el estilo de cita que necesites: APA, MLA, Harvard, Vancouver, Chicago, etc.

También puede descargar el texto completo de la publicación académica en formato pdf y leer en línea su resumen siempre que esté disponible en los metadatos.

Explore libros sobre una amplia variedad de disciplinas y organice su bibliografía correctamente.

1

Barrowcliffe, Trevor W. Low molecular weight heparin. Chichester, West Sussex, England: Wiley, 1992.

Buscar texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
2

Hyers, Thomas M. Treatment handbook of low-molecular-weight heparin. London: Science Press, 2000.

Buscar texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
3

Thromoprophylaxis with low-molecular-weight heparins. London: Current Medicine Group, 2006.

Buscar texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
4

Christian, Doutremepuich, ed. Low molecular weight heparins in clinical practice. New York: Dekker, 1992.

Buscar texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
5

1940-, Kher André, Sarret Monique 1938- y Toulemonde Francis 1926-, eds. Low molecular weight heparin therapy: An evaluation of clinical trials evidence. New York: Marcel Dekker, 1999.

Buscar texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
6

Holmer, Erik. Heparin and its low molecular weight derivatives: Basic and applied studies in the development of a new antithrombotic drug. Uppsala: Sveriges Lantbruksuniversitet, 1987.

Buscar texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
7

Maguire, Jacinta Marie. Low molecular weight heparin regime or unfractionated heparin and as pirin in the treatment of unstable angina. [S.l: The Author], 1994.

Buscar texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
8

Shukla, Vijay K. Low molecular weight heparins for major orthopedic surgery: A case for clinical outcomes. Ottawa, Ont: Canadian Coordinating Office for Health Technology Assessment, 1998.

Buscar texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
9

Kampen, Thorsten U. Low Molecular Weight Organic Semiconductors. Weinheim, Germany: Wiley-VCH Verlag GmbH & Co. KGaA, 2010. http://dx.doi.org/10.1002/9783527629978.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
10

Bäckvall, Helena y Janne Lehtiö, eds. The Low Molecular Weight Proteome. New York, NY: Springer New York, 2013. http://dx.doi.org/10.1007/978-1-4614-7209-4.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
11

Nightingale, Philip D. Low molecular weight halocarbons in seawater. Norwich: University of East Anglia, 1991.

Buscar texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
12

Haug, G. y H. Hoffmann, eds. Pyrethroid Residues, Immunoassays for Low Molecular Weight Compounds. Berlin, Heidelberg: Springer Berlin Heidelberg, 1990. http://dx.doi.org/10.1007/978-3-642-74846-2.

Texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
13

Blass, W. Pyrethroid residues, immunoassays for low molecular weight compounds. Berlin: Springer-Verlag, 1990.

Buscar texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
14

Bäckvall, Helena. The low molecular weight proteome: Methods and protocols. New York: Springer, 2013.

Buscar texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
15

Niemelä, Klaus. Low-molecular-weight organic compounds in birch kraft black liquor. Helsinki: Suomalainen Tiedeakatemia, 1990.

Buscar texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
16

Zhu, Yibo. Two-dimensional material-based nanosensors for detection of low-molecular-weight molecules. [New York, N.Y.?]: [publisher not identified], 2018.

Buscar texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
17

Astrid, Sigel y Sigel Helmut, eds. Probing of proteins by metal ions and their low-molecular-weight complexes. New York: Marcel Dekker, 2001.

Buscar texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
18

McCallum, N. K. A specific method for the analysis of low molecular weight phenols using pentafluorobenzyl ethers. Lower Hutt: Chemistry Division, Dept. of Scientific and Industrial Research, 1986.

Buscar texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
19

Layton, Guy Timothy. The immunogenicity and allergenicity of low molecular weight chemicals: Chlorhexidine as the model hapten. Birmingham: University of Birmingham, 1985.

Buscar texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
20

Pierson, Janice Rose. A study of the expression of the low molecular weight cytokeratins in cervical pearls. [S.l: The Author], 1991.

Buscar texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
21

L, Newton Gerald y United States. National Aeronautics and Space Administration., eds. Determination of low molecular weight thiols using monobromobimane fluorescent labeling and high-performance liquid chromatography. [Washington, DC]: National Aeronautics and Space Administration, 1988.

Buscar texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
22

Morales, Roman Padilla. High density polyethylene modified with a low molecular weight ionomer and the precursor acid copolymer. Ottawa: National Library of Canada, 1994.

Buscar texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
23

Yang, Jaeyoung. Micro and Nanoscale Aptasensors for Detection of Low Molecular Weight Biomarkers Towards Clinical Diagnostic Applications. [New York, N.Y.?]: [publisher not identified], 2015.

Buscar texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
24

Latorre, Sandra Stefanie. Formation of low molecular weight organic compounds from UV disinfection of chlorinated water containing humic substances. Ottawa: National Library of Canada, 2003.

Buscar texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
25

Blackwell, Malcolm Peter. Investigation of a biochemical marker of pulmonary eosinophil influx as a predictive assay for low molecular weight respiratory sensitisers. [Derby: University of Derby], 1999.

Buscar texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
26

Kägi, Jeremias H. R., 1930- y Kojima Yutaka 1933-, eds. Metallothionein II: Proceedings of the Second International Meeting on Metallothionein and Other Low Molecular Weight Metal-binding Proteins : Zürich, August 21-24, 1985. Basel: Birkhäuser Verlag, 1987.

Buscar texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
27

Laturnus, Frank. Bildung und Abgabe kurzkettiger halogenierter Kohlenwasserstoffe durch Makroalgen der Polarregionen =: Formation and release of low-molecular weight halogenated hydrocarbons by macroalgae from polar regions. Bremerhaven: Alfred-Wegener-Institut für Polar- und Meeresforschung, 1993.

Buscar texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
28

Low Molecular Weight Haparins. 3a ed. BC Decker Inc., 1998.

Buscar texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
29

Samama, Meyer M. Low Molecular Weight Heparin and Its Clinical Use: Journal: Haemostasis, Vol. 16, 1985 (Low Molecular Weight Heparin & Its Clinical Use). S. Karger AG (Switzerland), 1986.

Buscar texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
30

Low Molecular Weight Heparins. Decker Periodicals, Canada, 1994.

Buscar texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
31

Breddin, H. K. Low Molecular Weight Heparins. S Karger AG, 1988.

Buscar texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
32

Power, Trevor David. Derivatization of low molecular weight heparin with polyethylene glycol monomethyl ether (MPEG). 1995.

Buscar texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
33

Sarret/Kher/tou. Low Molecular Weight Heparin Therapy: An Evaluation of Clinical Trials Evidence. Informa Healthcare, 1999.

Buscar texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
34

Sarret, Monique, Andre Kher y Francis Toulemonde. Low Molecular Weight Heparin Therapy: An Evaluation of Clinical Trials Evidence. Taylor & Francis Group, 1999.

Buscar texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
35

Low-molecular-weight heparins in prophylaxis and therapy of thromboembolic diseases. New York: M. Dekker, 1994.

Buscar texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
36

Kakkar, V. V. Low-Molecular-Weight Heparins - New Fronteirs in Antithrombotic Therapy (Haemostasis). S Karger Pub, 1997.

Buscar texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
37

Low-Molecular-Weight Heparins: A New Therapeutic Approach to Thrombosis Proceedings (Journal - Haemostasis , Vol 26, Suppl. 2). S. Karger AG (Switzerland), 1996.

Buscar texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
38

MacCallum, Niall S. Management of oncological complications in the ICU. Oxford University Press, 2016. http://dx.doi.org/10.1093/med/9780199600830.003.0376.

Texto completo
Resumen
Important treatment complications relevant to critical care are discussed. Cancer-related pain is complex and requires multidisciplinary care, particularly in the peri-operative setting. Chemotherapeutic complications include pancytopenia, cardiac, pulmonary, renal, gastrointestinal, hepatic, and neurotoxicity. Radiotherapy complications include cardiac, pulmonary, and gastrointestinal toxicity. In general, management includes assessing the risk-benefit to cytotoxic therapy withdrawal and supportive care. There is a paucity of proven treatment options for most complications, althoughcertain therapies are used to prevent and/or treat complications (e.g. tumour lysis syndrome). Thromboembolic disease is a common cause of mortality and morbidity; low molecular weight heparin therapy may be superior to oral anticoagulation.
Los estilos APA, Harvard, Vancouver, ISO, etc.
39

Peppelenbosch, A. G. y Martijn Poeze. Ischaemic bowel in the critically ill. Oxford University Press, 2016. http://dx.doi.org/10.1093/med/9780199600830.003.0186.

Texto completo
Resumen
Intestinal ischaemia is caused by occlusion of the visceral arteries, thrombosis of the mesenteric veins, or by (low-flow) non-occlusive mesenteric ischaemia (NOMI). Each condition has a specific diagnostic and therapeutic work-up and prognostic significance. The incidence of acute mesenteric infarction is as low as 0.63 cases/100,000 person years, but overall mortality rates remains high at 74%. In general, a high index of suspicion is necessary and should be followed by administering therapeutic low molecular weight heparin or systemic heparin infusion. In these patients resuscitation and organ support are essential, but should not delay diagnostic work-up, including CT-angiography. With arterial occlusion, revascularization should be performed if indicated, preferentially using endovascular techniques prior to laparotomy. For venous occlusion, thrombolytic therapy directly into the superior mesenteric artery or venous thrombectomy can be performed, followed by laparotomy. The treatment of NOMI is to treat the underlying cause.
Los estilos APA, Harvard, Vancouver, ISO, etc.
40

Kilkelly, Shannon. Coagulation System. Editado por Matthew D. McEvoy y Cory M. Furse. Oxford University Press, 2017. http://dx.doi.org/10.1093/med/9780190226459.003.0090.

Texto completo
Resumen
Despite the development of entirely new classes of anticoagulant medication, vitamin K antagonists like warfarin continue to be commonly prescribed for a wide range of cardiovascular diagnoses. Conversely, the advent of low molecular weight heparin has greatly simplified the use of the drug to the point that patients can dose themselves at home with no need for any type of monitoring. Given the widespread use of these medications, it is not surprising that an increasing number of patients requiring urgent or emergent surgery will present with a medically induced coagulopathy. Managing this coagulopathy requires assessment of the urgency of the operation, the patient’s volume status, and the need for reanticoagulation following surgical intervention.
Los estilos APA, Harvard, Vancouver, ISO, etc.
41

Low Molecular Weight Organic Semiconductors. Vch Verlagsgesellschaft Mbh, 2009.

Buscar texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
42

Kampen, Thorsten U. Low Molecular Weight Organic Semiconductors. Wiley & Sons, Incorporated, John, 2010.

Buscar texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
43

Kampen, Thorsten U. Low Molecular Weight Organic Semiconductors. Wiley & Sons, Incorporated, John, 2011.

Buscar texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
44

Kampen, Thorsten U. Low Molecular Weight Organic Semiconductors. Wiley & Sons, Incorporated, John, 2011.

Buscar texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
45

Kampen, Thorsten U. Low Molecular Weight Organic Semiconductors. Wiley & Sons, Limited, John, 2010.

Buscar texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
46

Chong, Ji Y. y Michael P. Lerario. Cancer and Coagulopathy. Oxford University Press, 2016. http://dx.doi.org/10.1093/med/9780190495541.003.0019.

Texto completo
Resumen
Advanced cancer is well known to cause a procoagulant state. The formation of sterile platelet thrombin vegetations on cardiac valves (i.e., nonbacterial thromboembolic disease) and arterial thrombosis are common etiologies of stroke in these patients. Despite preventative therapy with antiplatelet agents or low-molecular-weight heparins, stroke in cancer often portends a poor prognosis.
Los estilos APA, Harvard, Vancouver, ISO, etc.
47

Ballal, Salma y Ian A. Greer. Thromboembolic disorders in pregnancy. Oxford University Press, 2016. http://dx.doi.org/10.1093/med/9780198713333.003.0037.

Texto completo
Resumen
Thromboembolism in pregnancy remains a major cause of direct maternal mortality in the Western world. Thromboembolic events in pregnancy are spread across the three trimesters but the puerperium is the time of greatest risk with a relative risk of around 20-fold compared to the non-pregnant patient. When compared to the non-pregnant population where distal deep vein thrombosis is most common, most events in pregnancy are iliofemoral and left sided. Given the multi-hit nature of the problem, awareness of risk factors is important. The two most significant single risk factors in pregnancy for thromboembolism are history of previous venous thromboembolism and thrombophilia. The identification of risk factors will guide the use of thromboprophylaxis and assist diagnosis; however, objective diagnosis is required. Prophylaxis and treatment focuses on low-molecular-weight heparin, which is considered safe in pregnancy.
Los estilos APA, Harvard, Vancouver, ISO, etc.
48

Bäckvall, Helena y Janne Lehtiö. Low Molecular Weight Proteome: Methods and Protocols. Springer New York, 2016.

Buscar texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
49

Zemskov, V. M. Immunomodulating Effects of a Low Molecular Weight RNA. Routledge, 1992.

Buscar texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
50

Hayden, John. Low molecular weight organic acids in forest soils. 1999.

Buscar texto completo
Los estilos APA, Harvard, Vancouver, ISO, etc.
También puede estar interesado en las bibliografías sobre el tema "Low molecular weight heparin" para otros tipos de fuentes:
Artículos de revistas Tesis
Ofrecemos descuentos en todos los planes premium para autores cuyas obras están incluidas en selecciones literarias temáticas. ¡Contáctenos para obtener un código promocional único!

Pasar a la bibliografía